ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$1.69
+0.00 (+0.00%)
Open$1.71
Previous Close$1.69
Day High$1.72
Day Low$1.65
52W High$4.46
52W Low$1.04
Volume—
Avg Volume5.34M
Market Cap583.88M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+1,202.4% upside
Current
$1.69
$1.69
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |
| Rev Growth | +19.4% | -7.3% | -1.4% |
| Debt/Equity | 1.42 | 1.47 | 1.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |